Cargando…

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heo, Sook-Kyoung, Noh, Eui-Kyu, Yu, Ho-Min, Kim, Do Kyoung, Seo, Hye Jin, Lee, Yoo Jin, Cheon, Jaekyung, Koh, Su Jin, Min, Young Joo, Choi, Yunsuk, Jo, Jae-Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718665/ https://www.ncbi.nlm.nih.gov/pubmed/33276759 http://dx.doi.org/10.1186/s12885-020-07701-8

Ejemplares similares

Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
por: Heo, Sook-Kyoung, et al.
Publicado: (2022)

The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2017)

Author Correction: Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2015)

CD45(dim)CD34(+)CD38(−)CD133(+) cells have the potential as leukemic stem cells in acute myeloid leukemia
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation
por: Heo, Sook-Kyoung, et al.
Publicado: (2022)

LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2016)

Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease
por: Choi, Yeong-Gon, et al.
Publicado: (2023)

LIGHT (TNFSF14) promotes the differentiation of human bone marrow-derived mesenchymal stem cells into functional hepatocyte-like cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2023)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)

Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity
por: Heo, Sook-Kyoung, et al.
Publicado: (2014)

Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
por: Kim, Kyung Eun, et al.
Publicado: (2018)

Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
por: Kim, Hyeyeong, et al.
Publicado: (2021)

Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy
por: Rudd, Sean G, et al.
Publicado: (2020)

The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C)
por: Tsuda, Masataka, et al.
Publicado: (2017)

The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
por: Lee, Saebom, et al.
Publicado: (2018)

Radotinib attenuates TGFβ -mediated pulmonary fibrosis in vitro and in vivo: exploring the potential of drug repurposing
por: Baek, Suji, et al.
Publicado: (2022)

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometry
por: Seo, Hyo-Bum, et al.
Publicado: (2017)

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
por: Do, Young Rok, et al.
Publicado: (2020)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Association between the Human Development Index and Confirmed COVID-19 Cases by Country
por: Heo, Min-Hee, et al.
Publicado: (2022)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

Effect of Dieckol, a Component of Ecklonia cava, on the Promotion of Hair Growth
por: Kang, Jung-Il, et al.
Publicado: (2012)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

Treatment of acute erythroleukaemia with high‐dose cytarabine in a cat with feline leukaemia virus infection
por: Park, Da Sol, et al.
Publicado: (2021)

Ara solar
por: Anguiano Valadez, Adolfo, 1917-
Publicado: (1974)

Cytarabine induces cachexia with lipid malabsorption via zippering the junctions of lacteal in murine small intestine
por: Park, Mi-Rae, et al.
Publicado: (2023)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
por: Shin, Seung-Hwan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_74rn3f4u5h46dvq7jhiv1c0tvp